Status
Conditions
Treatments
About
Prospective will be collected in a minimum of 300 patients presenting with an acquired segmental mandibular defect ≥ 2 cm secondary to OSSC removal and drugs-induced osteonecrosis, and who require mandibular reconstruction.
Full description
Data will be prospectively collected from at least 300 patients with acquired segmental mandibular defects of 2 cm or larger following resection of tumors or necrotic/infected tissue, all of whom require mandibular reconstruction.
The follow up (FU) will consist of standard of care (routine) procedures and data collection will be done at 3, 6, 12, 18 and up to 24 months after resection and/or reconstruction. The maximum FU for each patient within the registry will be 2 years after mandibular resection.
Data collection will include confounding baseline data, tumor characteristics, neurological function, patient reported outcomes, quality of life as well as anticipated procedure-related adverse events (AEs). Available images will be collected and evaluated centrally to determine the location, positioning, osseointegration, bone quantity and quality of the transplants.
Depending on the volume and quality of the collected data, different statistical analyses will be performed. Exploratory analyses will be conducted to find relationships between the different treatment modalities and their outcomes.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
The study includes patients with an initial pathological/histologic diagnosis of mandibular involvement by oral tumors (such as OSCC, osteosarcoma, and ameloblastoma), bisphosphonate- or immunomodulatory drug-induced osteonecrosis, and mandibular lesions from metastatic conditions originating from other sites including lung, breast, prostate, or kidney.
Age 18 years and older
Bisphosphonate related osteonecrosis of the mandible
Immunomodulatory drugs induced mandibular osteonecrosis
Patients presented with ameloblastoma affecting the mandible
Patients presented with osteosarcomas of the mandible
Patients presented with oral metastases related mandibular lesions that are indicated for segmental resection, common primary tumor sites include lung, breast, prostate and kidney
Undergoing primary curative treatment with segmental resection of the mandible ≥2 cm
Intention to undergo mandibular reconstruction with autologous bone using a primary (one-stage) or secondary (two-stage) approach
Informed consent obtained, ie:
Exclusion criteria
Intraoperative exclusion criteria:
Additional exclusion criterion:
• No osseous reconstruction with autologous bone performed within 18 months from resection
300 participants in 1 patient group
Loading...
Central trial contact
Maria Medina Giner; Marco Minoia, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal